08:03 AM EDT, 06/30/2025 (MT Newswires) -- Biogen (BIIB) said Monday it initiated dosing in its global phase 3 trial to evaluate the investigational drug, felzartamab, in adults with primary membranous nephropathy, a severe autoimmune kidney disorder with no approved treatments.

The company said the study will compare felzartamab to tacrolimus and enroll around 180 patients, with results expected in 2029.

The drugmaker said the study will assess remission rates at 104 weeks and track changes in proteinuria, anti-PLA2R antibody levels, and patient-reported outcomes.

The trial is one of three phase 3 studies Biogen launched this year for felzartamab, alongside programs in IgA nephropathy and late antibody-mediated kidney transplant rejection, it added.